Literature DB >> 28449458

Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia.

Xuyou Zhu1, Xia Fang2, Wei Chen3, Fei Han1, Ziling Huang1, Benfang Luo4, Pan Gu1, Long Zhang1, Weizhe Qiu1, Yu Zeng1, Weiwei Rui1,5, Xianghua Yi1.   

Abstract

BACKGROUND: Idiopathic nonspecific interstitial pneumonia (INSIP) presents with varying degrees of interstitial inflammation and fibrosis exhibiting a uniform appearance. Lack of knowledge on the underlying mechanisms of INSIP has contributed to few effective treatment strategies. Our study is designed to explore aberrantly expressed cytokines involvement in INSIP development.
METHODS: Oligo GEArray was employed to detect the expression of cytokines in INSIP patients, and idiopathic pulmonary fibrosis (IPF) was setup as isotype control. Real-time PCR and immunohistochemistry analysis were used to further confirm the expression of abnormally expressed cytokines. The correlationship between cytokines expression and overall survival rate of patients with IPF and INSIP were analyzed.
RESULTS: From microarray detection, transforming growth factor-beta-1 (TGF-β1), fibroblast growth factor 10 (FGF10), and platelet derived growth factor (PDGF) were predominantly up-regulated in patients with INSIP. Real-time PCR and immunohistochemistry also showed these cytokines was abnormally expressed in INSIP. In addition to, the clinical relevance analysis demonstrated relatively lower expression of PDGF patients had longer overall survival rate than those with higher expression of PDGF.
CONCLUSIONS: Our study suggests that TGF-β1, FGF10, and PDGF are required for the pathogenesis of INSIP, and may therefore be ideal targets in INSIP treatment. Moreover, INSIP patients with lower expression of PDGF had better survival rate.

Entities:  

Keywords:  Idiopathic nonspecific interstitial pneumonia (INSIP); fibroblast growth factor 10 (FGF10); idiopathic pulmonary fibrosis (IPF); platelet derived growth factor (PDGF); transforming growth factor-beta-1 (TGF-β1)

Year:  2017        PMID: 28449458      PMCID: PMC5394091          DOI: 10.21037/jtd.2017.02.50

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

1.  [Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia].

Authors:  Li Gu; Wen-bing Xu; Hong-rui Liu; Zi-jian Guo; Xing-xiang Xu; Yuan-jue Zhu
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2003-06

Review 2.  Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes?

Authors:  Naftali Kaminski; Ivan O Rosas
Journal:  Proc Am Thorac Soc       Date:  2006-06

3.  TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.

Authors:  Lynne A Murray; Qingsheng Chen; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Xueyang Peng; Mridu Gulati; Robert J Homer; Thomas Russell; Nico van Rooijen; Jack A Elias; Cory M Hogaboam; Erica L Herzog
Journal:  Int J Biochem Cell Biol       Date:  2010-10-29       Impact factor: 5.085

4.  Cytokine regulation of lung fibroblast proliferation. Pulmonary and systemic changes in asbestos-induced pulmonary fibrosis.

Authors:  I Lemaire; H Beaudoin; C Dubois
Journal:  Am Rev Respir Dis       Date:  1986-10

Review 5.  Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator.

Authors:  Jeffrey J Swigris; Ware G Kuschner; Jennifer L Kelsey; Michael K Gould
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

6.  Gene expression profiling of familial and sporadic interstitial pneumonia.

Authors:  Ivana V Yang; Lauranell H Burch; Mark P Steele; Jordan D Savov; John W Hollingsworth; Erin McElvania-Tekippe; Katherine G Berman; Marcy C Speer; Thomas A Sporn; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2006-09-22       Impact factor: 21.405

7.  A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.

Authors:  Z D Daniil; F C Gilchrist; A G Nicholson; D M Hansell; J Harris; T V Colby; R M du Bois
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

Review 8.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

9.  Variable expression of platelet-derived growth factor family proteins in acute lung injury.

Authors:  J Walsh; M Absher; J Kelley
Journal:  Am J Respir Cell Mol Biol       Date:  1993-12       Impact factor: 6.914

10.  Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice.

Authors:  A Maeda; K Hiyama; H Yamakido; S Ishioka; M Yamakido
Journal:  Chest       Date:  1996-03       Impact factor: 9.410

View more
  3 in total

1.  Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Toru Arai; Masaki Hirose; Tomoko Kagawa; Kazuyoshi Hatsuda; Yoshikazu Inoue
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

Review 2.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

3.  Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Authors:  Nikhil Hirani; Alison C MacKinnon; Lisa Nicol; Paul Ford; Hans Schambye; Anders Pedersen; Ulf J Nilsson; Hakon Leffler; Tariq Sethi; Susan Tantawi; Lise Gravelle; Robert J Slack; Ross Mills; Utsa Karmakar; Duncan Humphries; Fredrik Zetterberg; Lucy Keeling; Lyn Paul; Philip L Molyneaux; Feng Li; Wendy Funston; Ian A Forrest; A John Simpson; Michael A Gibbons; Toby M Maher
Journal:  Eur Respir J       Date:  2021-05-27       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.